2017;136(14):1276-1283. 364. Ntaios G, Lip GY, Makaritsis K, et al. CHADS(2), CHA(2)S(2) DS(2)-VASc, and long-term stroke outcome in patients without atrial brillation. Neurology. 2013;80(11):1009-1017. 365. Ntaios G, Papavasileiou V, Lip GY, et al. Embolic stroke of undetermined source and detection of atrial brillation on follow- up: how much causality is there? J Stroke Cerebrovasc Dis. 2016;25(12):2975-2980. 366. Ntaios G, Lip GYH, Vemmos K, et al. Age- and sex-speci c analysis of patients with embolic stroke of undetermined source. Neurology. 2017;89(6):532-539. 367. Gorenek B, Bax J, Boriani G, et al. Device-detected subclinical atrial tachyarrhythmias: de nition, implications and management-an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Paci c Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulaci n Card aca y Electro siolog a (SOLEACE). Europace. 2017;19(9):1556-1578. 368. Boriani G, Pettorelli D. Atrial brillation burden and atrial brillation type: Clinical signi cance and impact on the risk of stroke and decision making for long-term anticoagulation. Vasc Pharmacol. 2016;83:26-35. 369. Mairesse GH, Moran P, Van Gelder IC, et al. Screening for atrial brillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Paci c Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci n Card aca y Electro siolog a (SOLAECE). Europace. 2017;19(10):1589-1623. 370. Freedman B, Camm J, Calkins H, et al. Screening for atrial brillation: a report of the AF-SCREEN International Collaboration. Circulation. 2017;135(19):1851-1867. 371. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial brillation and the risk of stroke. N Engl J Med. 2012;366(2):120-129. 372. Freedman B, Boriani G, Glotzer TV, Healey JS, Kirchhof P, Potpara TS. Management of atrial high-rate episodes detected by cardiac implanted electronic devices. Nat Rev Cardiol. 2017;14(12): 701-714. 373. 